Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor
KIM, Kevin B, KEFFORD, Richard, GONZALEZ, Rene, OTT, Patrick A, LONG, Georgina V, GARDNER, Olivia S, OUELLET, Daniele, YANMEI XU, DEMARINI, Douglas J, LE, Ngocdiep T, PATEL, Kiran, LEWIS, Karl D, PAVLICK, Anna C, INFANTE, Jeffrey R, RIBAS, Antoni, SOSMAN, Jeffrey A, FECHER, Leslie A, MILLWARD, Michael, MCARTHUR, GrantA, HWU, Patrick
Published in Journal of clinical oncology (01.02.2013)
Published in Journal of clinical oncology (01.02.2013)
Get full text
Journal Article
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
Falchook, Gerald S, Dr, Lewis, Karl D, MD, Infante, Jeffrey R, MD, Gordon, Michael S, MD, Vogelzang, Nicholas J, MD, DeMarini, Douglas J, PhD, Sun, Peng, PhD, Moy, Christopher, MS, Szabo, Stephen A, BA, Roadcap, Lori T, MS, Peddareddigari, Vijay GR, MD, Lebowitz, Peter F, MD, Le, Ngocdiep T, MD, Burris, Howard A, MD, Messersmith, Wells A, MD, O'Dwyer, Peter J, Prof, Kim, Kevin B, MD, Flaherty, Keith, MD, Bendell, Johanna C, MD, Gonzalez, Rene, Prof, Kurzrock, Razelle, Prof, Fecher, Leslie A, MD
Published in The lancet oncology (01.08.2012)
Published in The lancet oncology (01.08.2012)
Get full text
Journal Article
Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial
Infante, Jeffrey R, Dr, Fecher, Leslie A, MD, Falchook, Gerald S, MD, Nallapareddy, Sujatha, MD, Gordon, Michael S, MD, Becerra, Carlos, MD, DeMarini, Douglas J, PhD, Cox, Donna S, PhD, Xu, Yanmei, MS, Morris, Shannon R, MD, Peddareddigari, Vijay GR, MD, Le, Ngocdiep T, MD, Hart, Lowell, MD, Bendell, Johanna C, MD, Eckhardt, Gail, MD, Kurzrock, Razelle, Prof, Flaherty, Keith, MD, Burris, Howard A, MD, Messersmith, Wells A, MD
Published in The lancet oncology (01.08.2012)
Published in The lancet oncology (01.08.2012)
Get full text
Journal Article
A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours
Infante, Jeffrey R, Papadopoulos, Kyriakos P, Bendell, Johanna C, Patnaik, Amita, Burris, Howard A, Rasco, Drew, Jones, Suzanne F, Smith, Lon, Cox, Donna S, Durante, Michael, Bellew, Kevin M, Park, Joohyun (Jennifer), Le, Ngocdiep T, Tolcher, Anthony W
Published in European journal of cancer (1990) (01.06.2013)
Published in European journal of cancer (1990) (01.06.2013)
Get full text
Journal Article
Inability of memory T cells to induce graft-versus-host disease is a result of an abortive alloresponse
Chen, Benny J., Deoliveira, Divino, Cui, Xiuyu, Le, Ngocdiep T., Son, Jessica, Whitesides, John F., Chao, Nelson J.
Published in Blood (01.04.2007)
Published in Blood (01.04.2007)
Get full text
Journal Article
Safety, pharmacokinetics, pharmacodynamics profiles and preliminary antitumor activity of phase 1b/2a study of NT-I7, a long-acting interleukin-7, plus pembrolizumab in patients with advanced solid tumors: The phase 1b data report
Naing, Aung, Fan, Jean, Lee, Byung Ha, Basudhar, Debashree, Pant, Shubham, Chaney, Marya F., Laviada, Cristina, Rajan, Cynthia, Le, Ngocdiep T., Barve, Minal A.
Published in Journal of clinical oncology (20.05.2021)
Published in Journal of clinical oncology (20.05.2021)
Get full text
Journal Article
The PRIMO study: A phase 2 study of duvelisib efficacy and safety in patients with relapsed or refractory peripheral t-cell lymphoma (PTCL)
Horwitz, Steven M., Soto, Jasminder, Youssoufian, Hagop, Lloyd, Deborah, Le, Ngocdiep T.
Published in Journal of clinical oncology (20.05.2018)
Published in Journal of clinical oncology (20.05.2018)
Get full text
Journal Article
A phase I/II study to evaluate the safety and efficacy of a novel long-acting interleukin-7, NT-I7, for patients with newly diagnosed high-grade gliomas after chemoradiotherapy: The interim result of the phase I data
Campian, Jian Li, Luo, Jingqin, Avvaru, Chai, Katumba, Ruth, Kim, Albert H, Dunn, Gavin P., Abraham, Christopher, Bhatta, Puspanjali, Yang, Se Hwan, Fan, Jean, Lee, Byung Ha, Ranjitka, Sunita, Le, Ngocdiep T., Ansstas, George, Johanns, Tanner Michael, Chheda, Milan G, Huang, Jiayi
Published in Journal of clinical oncology (20.05.2021)
Published in Journal of clinical oncology (20.05.2021)
Get full text
Journal Article
The effect of duvelisib, a dual inhibitor of PI3K-δ,γ, on components of the tumor microenvironment in previously untreated follicular lymphoma
Casulo, Carla, Goy, Andre, Van Eygen, Koen, Sancho, Juan-Manuel, Santiago, Mercadal, Johnson, Rod, Bouabdallah, Kamal, Sprott, Kam, Le, Ngocdiep T., Pachter, Jonathan A., Weaver, David T.
Published in Journal of clinical oncology (20.05.2018)
Published in Journal of clinical oncology (20.05.2018)
Get full text
Journal Article
Preliminary safety and efficacy of GX-I7, a long-acting interleukin-7, in combination with pembrolizumab in patients with refractory or recurrent metastatic triple negative breast cancer (mTNBC): Dose escalation period of Phase Ib/II study (KEYNOTE-899)
Sohn, Joohyuk, Park, Kyong Hwa, Ahn, Hee Kyung, Lee, Keun Seok, Kim, Jee Hyun, Kim, Sung-Bae, Lee, Kyoung Eun, Kim, Jee Hung, Yang, Se Hwan, Le, Ngocdiep T., Kim, Jiwon, Heo, MinKyu, Woo, Jung-Won, Sung, Young Chul, Im, Young Hyuck
Published in Journal of clinical oncology (20.05.2020)
Published in Journal of clinical oncology (20.05.2020)
Get full text
Journal Article
The efficacy of duvelisib monotherapy following disease progression on ofatumumab monotherapy in patients with relapsed/refractory CLL or SLL in the DUO crossover extension study
Kuss, Bryone J., Davids, Matthew Steven, Hillmen, Peter, Essell, James H., Moreno, Carol, Lamanna, Nicole, Nagy, Zsolt, Tam, Constantine Si Lun, Stilgenbauer, Stephan, Jäger, Ulrich, Ghia, Paolo, Delgado, Julio, Le, Ngocdiep T., Jeglinski, Brenda, Montillo, Marco
Published in Journal of clinical oncology (20.05.2018)
Published in Journal of clinical oncology (20.05.2018)
Get full text
Journal Article
Duvelisib inhibition of chemokines in patients with CLL (DUO study) and iNHL (DYNAMO study)
Weaver, David T., Sprott, Kam, Pachter, Jonathan, Le, Ngocdiep T., Davids, Matthew Steven, Montillo, Marco, Illés, Árpád, Etienne, Gabriel, Delgado, Julio, Kuss, Bryone J., Tam, Constantine, Offner, Fritz, Lunin, Scott D., Bosch, Francesc, Hillmen, Peter, Lamanna, Nicole, Stilgenbauer, Stephan, Zinzani, Pier Luigi, Flinn, Ian, Brown, Jennifer R.
Published in Journal of clinical oncology (20.05.2018)
Published in Journal of clinical oncology (20.05.2018)
Get full text
Journal Article
Circulating cytokines and angiogenic factors (CAF) as markers of clinical response in the study of trametinib (T) plus gemcitabine (G) versus placebo (P) plus gemcitabine for patients (pts) with untreated metastatic adenocarcinoma of the pancreas (MEK113487)
Heymach, John, Tran, Hai T., Nixon, Andrew B., Hurwitz, Herbert, Infante, Jeffrey R., Gagnon, Robert C., Steplewski, Klaudia, Le, Ngocdiep T., Liu, Yuan
Published in Journal of clinical oncology (20.05.2013)
Published in Journal of clinical oncology (20.05.2013)
Get full text
Journal Article
A randomized, double-blind, placebo-controlled trial of trametinib, a MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas
Infante, Jeffrey R., Somer, Bradley G., Park, Joon Oh, Li, Chung-Pin, Scheulen, Max E., Kasubhai, Saifuddin M., Oh, Do-Youn, Liu, Yuan, Lahiri, Soumi, Steplewski, Klaudia, Le, Ngocdiep T.
Published in Journal of clinical oncology (01.02.2013)
Published in Journal of clinical oncology (01.02.2013)
Get full text
Journal Article
A phase lb, open-label, multicenter, dose-escalation study of the oral pan-PI3K inhibitor BKM120 in combination with the oral MEK1/2 inhibitor GSK1120212 in patients (pts) with selected advanced solid tumors
Bedard, Philippe, Tabernero, Josep, Kurzrock, Razelle, Britten, Carolyn D., Stathis, Anastasios, Perez-Garcia, Jose Manuel, Zubel, Angela, Le, Ngocdiep T., Carter, Kirsten, Bellew, Kevin M., Gallarati, Chiara, Niazi, Faiz, Demanse, David, De Buck, Stefan S., Sessa, Cristiana
Published in Journal of clinical oncology (20.05.2012)
Published in Journal of clinical oncology (20.05.2012)
Get full text
Journal Article
Activity of the MEK Inhibitor Trametinib (GSK1120212) in Advanced Melanoma in a Phase I, Dose-escalation Trial
Falchook, Gerald S, Lewis, Karl D, Infante, Jeffrey R, Gordon, Michael S, Vogelzang, Nicholas J, DeMarini, Douglas J, Sun, Peng, Moy, Christopher, Szabo, Stephen A., Roadcap, Lori T, Peddareddigari, Vijay G R, Lebowitz, Peter F, Le, Ngocdiep T, Burris, Howard A, Messersmith, Wells A, O'Dwyer, Peter J, Kim, Kevin B., Flaherty, Keith, Bendell, Johanna C., Gonzalez, Rene, Kurzrock, Razelle, Fecher, Leslie A
Published in The lancet oncology (16.07.2012)
Published in The lancet oncology (16.07.2012)
Get full text
Journal Article
Abstract B128: A phase IB study of the MEK inhibitor GSK1120212 combined with everolimus in patients with solid tumors: Interim results
Infante, Jeffrey R., Patnaik, Amita, Jones, Suzanne F., Papadopoulos, Kiriakos P., Bendell, Johanna C., Rasco, Drew W., Bellew, Kevin M., Cox, Donna S., Durante, Michael G., Park, Joohyun J., Burris, Howard A., Le, Ngocdiep T., Tolcher, Anthony W.
Published in Molecular cancer therapeutics (12.11.2011)
Published in Molecular cancer therapeutics (12.11.2011)
Get full text
Journal Article
NOVEL PHARMACEUTICAL COMPOSITION
Demarini, Douglas, J, Le, Ngocdiep T, Wang, Lihong, Henriquez, Francisco
Year of Publication 16.08.2024
Get full text
Year of Publication 16.08.2024
Patent
NOVEL PHARMACEUTICAL COMPOSITION
Le, Ngocdiep T, Wang, Lihong, Henriquez, Francisco, DeMarini, Douglas J
Year of Publication 27.11.2020
Get full text
Year of Publication 27.11.2020
Patent